Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Draft Position Paper Released on BRONJ and Treatment with Bisphosphonates
August 10, 2009
- DPJ Supports Promotion of the Use of Generics: Dr Adachi
August 10, 2009
- SMUD to Become Operational to Monitor Use of Thalidomide Imported for Personal Use
August 10, 2009
- JPA Vice President Conditionally Supports Industry-Proposed Pricing System Reform
August 10, 2009
- Diabetes and Osteoporosis Are Related: Prof. Okazaki
August 10, 2009
- Share of Generics Up 1.9 Points to 18.0% on a Volume Basis
August 3, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 3, 2009
- Kure City to Save Over ¥100 Mil. by Generics Use-Promotion Notification Service
August 3, 2009
- Bayer Schering Aims at Becoming One of World's Top-Five Oncology Companies: Mr R. Rosen
August 3, 2009
- Generic Firms Should Ally to Improve Image of Generics: Mr Kinoshita
August 3, 2009
- Chugai Keeps Top Position in Japanese Oncology Market
August 3, 2009
- Hodanren Opposed to Promotion of Use of Generics That Neglect Reality
August 3, 2009
- NBI Aims at Sales of ¥17 Bil. for Spiriva
August 3, 2009
- JLHWO to Conduct More Clinical Trials at Rosai Hospitals
August 3, 2009
- Recomodulin to Grow Big in FY2011: Asahi Kasei Pharma
August 3, 2009
- R&D NEWS IN BRIEF
August 3, 2009
- Kyowa Kirin to Increase Focus on Diagnostics: Dr Matsuda
August 3, 2009
- Reports of Malfunctions from Marketers Show Sharp Decrease in FY2008
August 3, 2009
- Nippon Chemiphar to Decide Its Relationship with Ranbaxy Soon
August 3, 2009
- MEDICAL DEVICE NEWS IN BRIEF
August 3, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…